

*b8
and*
42, 134-139, 155, and 157 of SEQ ID NO: 6; while site C contacts correspond in IL-1 ϵ to amino residues 81-106 of SEQ ID NO: 6. Corresponding residues should be important in the primate sequence (see SEQ ID NO: 13 and 15).--

IN THE CLAIMS:

Please amend Claim 25, as indicated.

25. (Amended Once) The binding compound of claim 24, wherein said 12 consecutive amino acid segment is selected from:

B7C7
B9

- (1) LeuCysPheArgMetLysAspSerAlaLeuLysValLeuTyrLeuHisAsn-Asn (residues 8-25 of SEQ ID NO:2);
- (2) IleSerValValProAsnArgAlaLeuAspAlaSerLeuSerProValIle-LeuGlyValGln (residues 43-63 of SEQ ID NO:2);
- (3) SerProValIleLeuGlyVa|GlnGlyGlySerGlnCys (residues 56-68 of SEQ ID NO:2);
- (4) ProlleLeuLysLeuGluProValAsnIleMetGluLeu (residues 77-89 of SEQ ID NO:2);
- (5) ThrSerSerPheGluSerAlaAlaTyrProGlyTrpPhe (residues 109-121 of SEQ ID NO:2);
- (6) PheLeuCysThrSerProGluAlaAspGlnProVal (residues 121-132 of SEQ ID NO:2);
- (7) ThrGlnIleProGluAspProAlaTrpAspAlaProlle (residues 135-147 of SEQ ID NO:2);

or

- (8) ThrSerSerPheGluSerAlaAlaTyrProGlyTrpPhe (residues 109-121 of SEQ ID NO:2).

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."